消栓肠溶胶囊对高血压伴心血管危险因素患者血清PAF含量的影响

Effect of Xiaoshuan Enteric-coated Capsule on Platelet Activating Factor in Hypertension Patients with Cardiovascular Risk Factors

目的:探讨中药复方制剂消栓肠溶胶囊对高血压伴心血管危险因素患者血小板活化因子(PAF)含量的影响。方法:将高血压伴心血管危险因素患者随机分为消栓肠溶胶囊组30例和阿司匹林组30例,另选30名健康人为健康对照组,检测治疗前后血清PAF含量的变化。结果:高血压伴心血管危险因素患者血清PAF含量消栓肠溶胶囊组和阿司匹林组治疗前分别为(28.05±7.40)ng/mL和(27.51±7.61)ng/mL,经治疗后分别为(8.67±3.93)ng/mL和(11.36±3.03)ng/mL,消栓肠溶胶囊治疗后其降低PAF含量的作用明显优于拜阿司匹林(P<0.01)。结论:临床抗栓治疗均可明显降低高血压伴心血管危险因素患者的血清PAF含量,而消栓肠溶胶囊组下降更为明显,体现了中药复方消栓肠溶胶囊多途径、多靶点降低患者血清PAF含量的优势。

Objective： To investigate the effect of Xiaoshuan enteric-coated capsules（XSECC） on platelet activating factor （PAF） activity in hypertension patients with cardiovascular risk factors. Methods： Sixty hypertension patients were randomly divided into XSECC group（n=30） and aspirin group（n=30）, and thirty healthy volunteers served as healthy control group. Serum PAF content was detected before and after treatment. Results： ~AF content was（28.05 ＋ 7.40）ng/mL and（27.51 ＋ 7.61）ng/mL before treatment, and was（8.67 ＋ 3.93）ng/mL and （11.36 ＋ 3.03）ng/mL after treatment in XSECC group and Aspirin group.After treatment, PAF content of XSECC group was obviously lower than that of aspirin group（P 〈 0.01）. Conclusion, The clinical antithrombotic therapy can significantly reduce PAF content of hypertension patients with cardiovascular risk factors, while the decrease of XSECC group is more obvious, indicating that XSECC is able to reduce serum PAF content through multiple ways and by multiple targets.